作者采用不同的抗原类型[葡萄球菌肠毒素B(SEB)类毒素或蛋白体-SEB类毒素]、接种途径(鼻内和胃肠道外)及免疫程序在小鼠中测定蛋白体-SEB类毒素菌苗的免疫原性和小鼠抵御致死性SEB攻击的能力.作者将由B群脑膜炎球菌制备的蛋白体与SEB类毒素结合制成菌苗,每剂菌苗的Al(OH)_3含量为4.34mg/ml.用聚丙烯酰胺凝胶电泳、体内脱毒试验和鼠脾淋巴细胞增殖试验进行类毒素鉴定和脱毒的确证.用ELISA法测定血清中抗-SEB IgG抗体和肺、肠洗液中IgA抗体.用SEB攻击试验测定菌苗在体内的效力. The authors tested proteosome-SEB toxoids in mice using different antigen types (SEB toxoid or proteosome-SEB toxoid), route of vaccination (intranasal and parenteral), and immunization procedures The immunogenicity of the vaccine and the ability of the mice to resist the lethal SEB challenge.The authors prepared the bacterins prepared by the meningococcal group B meningococcal and SEB toxoid and the amount of Al (OH) 3 per vaccine was 4.34mg / ml.Using polyacrylamide gel electrophoresis, in vivo detoxification test and splenic lymphocyte proliferation test for confirmation of toxoid identification and detoxification.Serum anti-SEB IgG antibody and lung, intestinal wash Liquid IgA Antibodies The efficacy of the vaccine in vivo was determined using the SEB challenge assay.